“It's really the overall excellence of a multidisciplinary program focused on improving patient outcomes,” says Daniel E. Spratt, MD.
In this video, Jonathan E. Shoag, MD, and Daniel E. Spratt, MD, discuss University Hospitals Cleveland Medical Center being named the first SpaceOAR Hydrogel Center of Excellence as well as the importance of multidisciplinary care in treating prostate cancer. Shoag is a urologist at University Hospitals and an assistant professor of urology at Case Western Reserve University School of Medicine, and Spratt is chair of Radiation Oncology at UH Cleveland Medical Center and a professor at Case Western Reserve University School of Medicine.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.